Diplomat Pharmacy Inc (DPLO) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $0.23 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $0.21. The company posted revenue of $1089.00 million in the period, compared to analysts expectations of $1118.15 million. The company’s revenue was up 34.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.16 EPS.
Many Wall Street Analysts have commented on Diplomat Pharmacy Inc. Diplomat Pharmacy Inc was Resumed by BofA/Merrill to “Neutral” on Jun 7, 2016.
Diplomat Pharmacy Inc closed down -0.89 points or -2.36% at $36.87 with 3,16,863 shares getting traded on Monday. Post opening the session at $37.77, the shares hit an intraday low of $36.73 and an intraday high of $37.83 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Aug 2, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 12,325 shares at $35.88 per share price. According to the SEC, on Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at $33.60 per share price. On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at $35.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.